Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $1.8 million.

  • Agios Pharmaceuticals' Change in Account Payables fell 7450.98% to $1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 4418.3%. This contributed to the annual value of $6.6 million for FY2024, which is 17558.69% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Change in Account Payables is $1.8 million, which was down 7450.98% from $3.9 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Change in Account Payables peaked at $8.1 million during Q4 2022, and registered a low of -$9.8 million during Q1 2023.
  • Over the past 5 years, Agios Pharmaceuticals' median Change in Account Payables value was $1.4 million (recorded in 2024), while the average stood at $318842.1.
  • In the last 5 years, Agios Pharmaceuticals' Change in Account Payables soared by 55020.24% in 2021 and then tumbled by 29727.27% in 2025.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Change in Account Payables stood at $5.2 million in 2021, then skyrocketed by 55.08% to $8.1 million in 2022, then crashed by 143.8% to -$3.5 million in 2023, then surged by 78.6% to -$756000.0 in 2024, then soared by 339.02% to $1.8 million in 2025.
  • Its last three reported values are $1.8 million in Q3 2025, $3.9 million for Q2 2025, and -$2.8 million during Q1 2025.